Healthcare
Live Price
Offline$59.01
+4.59% today
Window Change
+13.50%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
GeneDx Holdings Corp. (WGS) is a Healthcare stock with a market cap of $1.99B and listed on NASDAQ. The stock last traded around $59.01 and up 13.5% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +40.0%, EPS growth of +62.4%, a dividend yield of 0.0%. What stands out right now is revenue +40.0%, EPS +62.4%, free cash flow +142.0% with operating margin -2.9% and ROIC -2.7%. Valuation sits in the middle of the pack at price/sales 4.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines WGS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WGS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WGS Max Drawdown
-7.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WGS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$212.2M
-9.6% YoY
FY Net Income
-$245.4M
+55.3% YoY
Free Cash Flow
-$211.2M
+36.7% YoY
Revenue Growth
+40.0%
EPS Growth
+62.4%
Gross Margin
68.5%
Net Margin
-4.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 428M | 305M | 203M | 235M | 212M |
| Gross Profit | 298M | 194M | 90M | -27M | -17M |
| Operating Income | -12M | -23M | -181M | -668M | -446M |
| EBITDA | 7M | -1M | -136M | -398M | -221M |
| Net Income | -21M | -52M | -176M | -549M | -245M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 105M | 85M | 100M | 137M | 401M |
| Total Assets | 570M | 419M | 419M | 545M | 554M |
| Total Liabilities | 262M | 174M | 191M | 292M | 166M |
| Shareholder Equity | 308M | 245M | 228M | 254M | 388M |
| Total Debt | 152M | 116M | 120M | 77M | 33M |
| Net Debt | 47M | 31M | 20M | -60M | -368M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
190M
+40.3% YoY
Capital Expenditures
21M
-45.1% YoY
Free Cash Flow
211M
+36.7% YoY
Key ratios
Gross Margin
68.5%
Operating Margin
-2.9%
Net Margin
-4.9%
ROE
-7.4%
Debt / Equity
0.49x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.